Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07800871 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FT839 in Autoimmune Diseases

Name: FT839 in Autoimmune Diseases — clinical trial record (NCT07800871)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorFate Therapeutics

Started2026-10

View on ClinicalTrials.gov ↗

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.

Trial Details

NCT Number	NCT07800871
Lead Sponsor	Fate Therapeutics
Conditions	ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Enrollment	446 participants
Start Date	2026-10
Primary Completion	2028-10 (estimated)
Study Completion	2040-10 (estimated)
Updated on ClinicalTrials.gov	2026-09-02